Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
(VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers October 14, 2026 8:00 AM EDT Julissa Viana - Vice President of Corporate Communications & Investor RelationsDaniel Paterson - President, CEO & DirectorMichael Glen Kauffman - President of Development & DirectorTing-Hui Wu Manuel Hidalgo MedinaMichael Schmidt - Guggenheim Securities, LLC, Research DivisionGraig Suvannavejh - Mizuho Securities USA LLC, Research DivisionEric Schmidt - Cantor Fitzgerald & Co., Research DivisionJeet Mukherjee - BTIG, LLC, Research DivisionYuan Zhi - B.
Riley Securities, Inc., Research DivisionJoshua Wolfson - RBC Capital Markets, Research DivisionKalpit Patel - Wolfe Research, LLCMatthew Venezia - Alliance Global Partners, Research Division Julissa VianaVice President of Corporate Communications & Investor Relations Good morning, everyone.
For those that don't know me, I'm Julissa Viana, the Senior Vice President of Corporate Communications, Investor Relations and Patient Advocacy.
We're really excited to have you here today, and thank you for those that are listening via the live stream.
Please note that this event is being recorded and will be available on our website afterwards.
This morning, we are very excited to discuss VS-7375, our best-in-class, highly selective oral KRAS G12D ON/OFF inhibitor, which is being evaluated in multiple clinical trials.
Today, we'll share new clinical data from our TARGET-D 101 trial, including for the first time, U.S.
efficacy data and updated safety and tolerability results in KRAS G12D mutated pancreatic, colorectal and lung cancers.
This morning, we issued a very long press release detailing these results, along with a slide presentation that we'll reference today.
I won't be reading the slide, but I do need to point out that we'll be making forward-looking statements that are based on our.
| Product | Price | Change |
|---|---|---|
| Brent Crude | $102.14/bbl | +0.34% |
| WTI Crude | $96.90/bbl | +0.21% |
| EN590 Diesel | $846/MT | +0.18% |
| Jet Fuel A-1 | $1090/MT | +0.55% |
| Mazut M100 | $450/MT | -0.15% |
| Bitumen 60/70 | $470/MT | +0.08% |
| Sulphur Gran 99.5% | $470/MT | -0.44% |
| Urea 46% Gran | $650/MT | +1.12% |
| NPK 16-16-16 | $460/MT | -0.28% |
| Nat Gas TTF | $15.42/MMBtu | +0.92% |
Comments
Post a Comment